Document is current
Any future updates will be listed below
-
Authors
Vester, Johannes C.
Buzoianu, Anca D.
Florian, Stefan I.
Hömberg, Volker
Kim, Se-Hyuk
Lee, Tatia M. C.
Matula, Christian
Poon, Wai Sang
Sandesc, Dorel
von Steinbüchel, Nicole
Strilciuc, Stefan
Vos, Pieter E.
von Wild, Klaus
Muresanu, Dafin https://orcid.org/0000-0002-9536-1153
- License Information
-
More Information
Article History
Received: 15 October 2020
Accepted: 7 December 2020
First Online: 23 February 2021
Compliance with ethical standards
:
: The CAPTAIN I trial has received an unrestricted research grant from Ever Neuro Pharma GmbH, the manufacturer of Cerebrolysin.
: CAPTAIN I: (NCT01606111) and local IRB approval.CAPTAIN II: Ethics Committee of the University of Medicine and Pharmacy in Cluj-Napoca, Romania (No. 714/07.03.2013); ISRCTN registry (No.:17097163).
: Investigators obtained written informed consent from all study participants.
: This manuscript was drafted without financial support.
: Informed consent was obtained from all individual participants included in the study.
